Solventum Corp.: Q4 FY2025 earnings call

What management said about Q4 FY2025, from the documents filed with the SEC on 26 February 2026: press release. Guidance figures: 3 new. The quarter’s numbers.

Read the filing

Key takeaways

• Organic growth rose across all segments: Reported sales fell 3.7% to $2 billion and organic sales rose 3.5%. Management tied organic growth to positive performance from all segments, led by MedSurg's infection prevention business and Dental Solutions. Source
• Debt paydown lifted adjusted EPS: Management said debt paydown after the Purification and Filtration sale was the main driver of higher adjusted EPS; quarterly adjusted diluted EPS was $1.57 against $1.41. Source
• Dental Solutions grew fastest organically: Dental Solutions sales were $343 million, up 8.6% reported and 5.9% organic, the highest organic growth among the business segments shown. Source
• Gain on sale lifted GAAP EPS: Full-year diluted EPS was $8.88 against $2.76, with net income of $1,556 million, helped by a $1,549 million pre-tax gain on sale of business, tied in the release to Purification and Filtration and a Health Information Systems business. Source
• Full-year adjusted EPS declined: Full-year adjusted diluted EPS was $6.11 against $6.70, a decline of 8.8%. Source
• Quarterly free cash flow fell: Operating cash flow was $96 million against $219 million, and free cash flow was $33 million against $92 million. Source
• Debt repayments reduced borrowings: Debt repayments in 2025 were $3,070 million; long-term debt fell to $5,035 million from $7,810 million, and cash was $878 million at year end. Source

“Solventum’s fourth quarter results reflect another quarter of solid performance resulting in full year 2025 results ahead of our expectations for sales and EPS,”

Bryan Hanson, chief executive officer of Solventum

Guidance

What changed from last quarter

• New guidance: Full-year 2026 guidance introduced; the release does not restate full-year 2025 guidance. Source
• New: Acera, acquired in December 2025, is included in the acquisitions sales impact for the first 12 months after the deal. Source

Quarter results and drivers

• Organic growth rose across all segments: Reported sales fell 3.7% to $2 billion and organic sales rose 3.5%. Management tied organic growth to positive performance from all segments, led by MedSurg's infection prevention business and Dental Solutions. Source
• Debt paydown lifted adjusted EPS: Management said debt paydown after the Purification and Filtration sale was the main driver of higher adjusted EPS; quarterly adjusted diluted EPS was $1.57 against $1.41. Source
• GAAP EPS and net income rose: Quarterly GAAP diluted EPS was $0.36 against $0.17, and net income was $63 million against $30 million. Source

Segment sales in the quarter

• Dental Solutions grew fastest organically: Dental Solutions sales were $343 million, up 8.6% reported and 5.9% organic, the highest organic growth among the business segments shown. Source
• Infection Prevention sales grew within MedSurg: Infection Prevention and Surgical Solutions sales were $752 million, up 6.2% reported and 4.2% organic, within MedSurg sales of $1,235 million. Source
• Advanced Wound Care grew least: Advanced Wound Care sales were $483 million, up 3.8% reported and 1.7% organic, the lowest organic growth of the business segments shown. Source
• Health Information Systems sales rose: Health Information Systems sales were $348 million, up 3.7% reported and 3.2% organic. Source
• Purification and Filtration no longer in sales: Purification and Filtration contributed no sales this quarter after its September 2025 sale; the prior-year quarter had $177 million. Source

“our underlying momentum and the intentional steps we’ve taken in our transformation journey demonstrate clear progress towards achieving our long-range plan.”

Bryan Hanson, chief executive officer of Solventum

Costs, margins and gross profit

• Quarterly SG&A fell, annual SG&A rose: Quarterly SG&A fell 3.2% to $759 million, while full-year SG&A rose 10.7% to $3,080 million. Source
• R&D spending declined: Research and development expenses were $175 million in the quarter, down 12.1%, and $739 million for the year, down 4.6%. Source
• Gross margin declined in quarter: GAAP gross margin was 51.4% against 54.0%; adjusted gross margin was 53.5% against 56.2%. Source
• Operating margins largely unchanged: Management said GAAP and adjusted operating margins were largely consistent with the prior year; GAAP was 6.2% against 6.6%, adjusted 19.9% against 20.4%. Source
• Segment margins moved unevenly: MedSurg operating margin was 15.5% against 17.8%; Dental Solutions was 24.4% against 23.3%, and Health Information Systems 38.3% against 34.1%. Source

Full-year 2025 results

• Full-year sales rose modestly: Full-year net sales were $8,325 million, up 0.9% reported; organic growth for the year was 3.3%. Source
• Gain on sale lifted GAAP EPS: Full-year diluted EPS was $8.88 against $2.76, with net income of $1,556 million, helped by a $1,549 million pre-tax gain on sale of business, tied in the release to Purification and Filtration and a Health Information Systems business. Source
• Full-year adjusted EPS declined: Full-year adjusted diluted EPS was $6.11 against $6.70, a decline of 8.8%. Source
• Full-year adjusted margin fell: Full-year adjusted operating income margin was 20.5% against 22.0%; GAAP margin rose to 26.2% from 12.6%. Source

Cash flow, debt and capital

• Quarterly free cash flow fell: Operating cash flow was $96 million against $219 million, and free cash flow was $33 million against $92 million. Source
• Full-year free cash flow turned negative: Full-year free cash flow was $(10) million against $805 million; operating cash flow was $369 million against $1,185 million. Source
• Debt repayments reduced borrowings: Debt repayments in 2025 were $3,070 million; long-term debt fell to $5,035 million from $7,810 million, and cash was $878 million at year end. Source
• Acquisitions and sale proceeds in investing: Acquisitions cost $696 million net of cash acquired; proceeds from the sale of the business were $3,890 million. Source
• Capital spending held near prior year: Purchases of property, plant and equipment were $379 million for the year against $380 million, and $63 million in the quarter against $127 million. Source

Restructuring, deals and program costs

• Transform program drove restructuring: Quarterly restructuring costs were $52 million, primarily for the Transform for the Future program, and were excluded from adjusted results. Source
• Full-year restructuring employee costs: Full-year restructuring costs included $70 million of employee termination costs and $10 million of other costs, including third-party consulting. Source
• Acquisition costs excluded from adjusted: Transaction and retention costs of $12 million tied to an acquisition were excluded from adjusted results in the quarter. Source

Risks management discussed

• External: Incremental tariff headwinds were a cost pressure; management said expense savings and the divestiture benefit more than offset them on an adjusted basis. Source
• Financial: Spin-off and separation-related costs of $146 million pre-tax were recorded in the quarter and excluded from adjusted results. Source

Earlier plans management reported on

• Not stated: Management said it continues to deliver on its commitments and is making clear progress on the long-range plan. Source
• Ahead: Management said full-year 2025 results were ahead of its expectations for sales and EPS. Source

Other quarters

• Q2 FY2026 earnings call
• Q1 FY2026 earnings call
• Q3 FY2025 earnings call
• Q2 FY2025 results

Summarised with AI from the documents the company filed with the SEC. Every point is checked against the filing before it is shown: management’s own words word for word, figures against the line or table row they come from. A point that fails the check is left out. Source opens the filing at that line.